TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Date: 29-05-2025

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Audited Financial Results (Standalone & Consolidated) for the Quarter ended and Year Endon 31ST March, 2025.

Please find the enclosed herewith Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended on **31st March, 2025** along with Auditors Report thereon approved by the Board of Directors of the Company at its Meeting held on Thursday, May 29th, 2025 at A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai — 400079 at 06:00pm., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
This is for your information and record.
Thanking you.

For Tejnaksh Healthcare Limited

Rawandale

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Date: 29-05-2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, in respect of Audit Report for the year ended March 31,2025.

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended vide SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016, we do hereby confirm that the Statutory Auditors of M/s Maheshwari and Co, Chartered Accountants, have issued an Audit Report with unmodified Opinion on Annual Audited (Standalone and Consolidated) Financial Results for the year ended on March 31, 2025.

This is for your information and record.

Thanking you.
For Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR QUARTER & YEAR ENDED MARCH 31, 2025
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Year Ended	
	Mar-25 (Refer Note 4)	Dec-24 Unaudited	Mar-24 (Refer Note 4)	Mar-25 Audited	Mar-24 Audited
REVENUE					
Revenue from operations (net)	240.43	223.82	214.25	879.78	822.15
Other income	6.23	13.92	6.46	35.26	27.84
Total Income	**246.66**	**237.74**	**220.70**	**915.04**	**849.99**
EXPENSES					
Cost of Materials Consumed	0.09	0.05	5.98	0.23	15.78
Purchases of stock-in-trade	13.88	7.38	16.32	57.18	62.17
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	6.82	(0.48)	(7.65)	7.51	(9.86)
Employee benefits expense	21.67	16.93	20.31	76.91	79.33
Finance costs	4.02	11.25	14.97	37.60	68.59
Depreciation and amortization expense	15.01	17.15	19.69	78.84	80.02
Other expenses	81.59	64.12	70.16	290.38	310.80
Total Expenses	**143.08**	**116.40**	**139.78**	**548.65**	**606.83**
Profit before Exceptional Items & Tax	**103.58**	**121.34**	**80.92**	**366.39**	**243.16**
Exceptional Items	-	-	-	-	-
Profit/(Loss) Before Tax	**103.58**	**121.34**	**80.92**	**366.39**	**243.16**
Tax expense:					
Current tax	21.13	33.78	15.30	83.34	41.31
Deferred tax	7.09	15.62	5.08	20.90	20.60
Profit /(Loss) for the period/year	**75.35**	**71.94**	**60.55**	**262.15**	**181.25**
Other Comprehensive Income/(Loss)					
Items not be reclassified to profit or loss :					
Remeasurement of defined employee benefit plans	(0.49)	0.62	1.21	1.37	2.48
Income tax credit(expense) relating to above items	0.13	(0.16)	(0.31)	(0.34)	(0.62)
Total Other Comprehensive income for the year, net of tax	**(0.36)**	**0.46**	**0.91**	**1.03**	**1.86**
TOTAL COMPREHENSIVE INCOME (NET OF TAX) FOR THE PERIOD/YEAR	**74.99**	**72.40**	**61.46**	**263.18**	**183.10**
Paid Up Equity Share Capital (face value 5/- each	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year				1,525.16	1,261.98
Earnings per share (EPS)					
Basic and Diluted Earing Per Share	0.37	0.36	0.30	1.29	0.89
	Not Annualized				

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STANDALONE BALANCE SHEET AS AT MARCH 31, 2025
CIN : L85100MH2008PLC179034

(₹ in Lakhs)

Particulars	As At March 31, 2025	As At March 31, 2024
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	1,802.00	1,861.89
Goodwill	210.88	350.00
Intangible Assets	0.99	1.03
Intangible Assets Under Development	133.25	107.25
Right-of-Use Assets	-	0.70
Financial Assets		
Investments	106.01	106.01
Other Financial Assets	143.57	30.47
Other Non-Current Assets	4.00	8.32
Income Tax Assets	4.32	37.90
Total Non-Current Assets	**2,405.02**	**2,503.56**
Current Assets		
Inventories	36.95	44.46
Financial Assets		
Trade Receivables	175.27	45.20
Cash and Cash Equivalents	160.88	141.19
Bank Balances Other than above	3.58	252.94
Other Financial Assets	4.03	8.15
Other Current Assets	114.67	15.93
Current Tax Asset (net)	-	-
Total Current Assets	**495.38**	**507.88**
TOTAL ASSETS	**2,900.40**	**3,011.44**
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	1,015.68	1,015.68
Other Equity	1,525.16	1,261.98
Total equity	**2,540.84**	**2,277.66**
Liabilities		
Non Current Liabilities		
Financial Liabilities		
Borrowings	63.20	410.94
Other Financial Liabilities	44.75	55.81
Non Current Provision	11.35	10.18
Deferred Tax liabilities (Net)	148.76	127.52
Other Non Current Liabilities	8.64	-
Total Non Current Liabilities	**276.70**	**604.45**
Current Liabilities		
Financial Liabilities		
Borrowings	-	-
Lease Liabilities	-	0.76
Trade Payables		
Total outstanding dues of Micro Enterprises and Small Enterprises	0.06	0.06
Total outstanding dues of other than Micro Enterprises and Small Enterprises	15.38	13.65
Other Financial Liabilities	51.69	86.69
Other Current Liabilities	9.63	22.70
Current Provision	6.10	5.47
Total Current Liabilities	**82.86**	**129.32**
TOTAL LIABILITIES	**2,900.40**	**3,011.43**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025
CIN : L85100MH2008PLC179034

(₹ in Lakhs)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before tax	**366.39**	**243.16**
Adjustments for		
Depreciation and amortisation expense	78.84	80.02
Interest income	(13.42)	(17.95)
Finance costs	37.60	63.95
Bad debts	-	40.62
Net (gain)/loss on financial instruments	-	(0.05)
Provision for gratuity	3.17	0.27
Change in operating assets and liabilities		
(Increase)/Decrease in trade receivables	(130.07)	43.91
(Increase)/Decrease in inventories	7.51	(10.84)
Increase/(Decrease) in trade payables	1.73	(14.34)
(Increase) /Decrease in other financial assets	(108.98)	1.77
(Increase)/Decrease in other assets	(94.42)	47.80
Increase/(Decrease) in other financial liabilities	(46.09)	6.03
Increase/(Decrease) in other liabilities	(4.43)	(36.67)
Cash generated from operations	**97.83**	**447.68**
Less: Income taxes paid (net)	(49.76)	(33.07)
Net cash flows generated/(used) from operating activities (A)	**48.07**	**414.61**
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment and Intangibles	(18.19)	(42.46)
Intangible asset under development	(26.00)	(12.00)
Deletion of Intangible assets	139.12	
Movement in other bank balance	249.36	(71.35)
Interest received	13.42	17.95
Net cash flows generated/(used) in investing activities (B)	**357.71**	**(107.86)**
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of non current borrowings	(347.74)	(162.04)
Proceeds from current borrowings	-	-
Repayment of current borrowings	-	(5.50)
Principal element of lease payment	(0.76)	(1.00)
Interest paid	(37.60)	(62.84)
Net cash flows generated/(used) in financing activities (C)	**(386.10)**	**(231.38)**
Net increase (decrease) in cash and cash equivalents (A+B+C)	19.69	75.37
Cash and Cash Equivalents at the beginning of the financial year	141.19	65.82
Cash and Cash Equivalents at end of the year	**160.88**	**141.19**
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with banks in current accounts	48.49	45.95
Cash on hand	112.39	95.24
Balances per statement of cash flows	**160.88**	**141.19**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Notes to the Audited Standalone Financial Results for the yearended March 31, 2025

1. The above audited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May29, 2025. The Statutory Auditors of the Company have carried out audit of the standalone financial results for the yearended March 31, 2025, and have issued an unmodified opinion on the same.

2. The above audited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. As the Company operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

4. The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the figures for the audited financial year and year to date unaudited figures up to the third quarter of the respective financial year. The figures up to the third quarter of the current financial year has been reviewed by auditors.

5. During the Quarter, following an arbitration award of ₹170 lakhs related to a non-compete dispute from a 2016 - 17 business acquisition, the Company adjusted the net proceeds of ₹139.12 lakhs (after deducting ₹30.88 lakhs in legal costs) against the original goodwill of ₹350 lakhs. The revised goodwill of ₹210.88 lakhs will be amortized over five years from FY 2025–26 in line with Ind AS 8, reflecting a change in the estimated pattern of economic benefits. An impairment review under Ind AS 36 confirmed no impairment was necessary as of the reporting date.

6. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: May 29, 2025
Place: Mumbai

Independent Auditor's Report on the Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Tejnaksh Healthcare Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying statement of standalone annual financial results of Tejnaksh Healthcare Limited (the "Company") for the quarter and financial year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

i. is presented in accordance with the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the quarter and financial year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "*Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results*" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal

financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone annual financial results that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledge user of standalone annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone annual financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter and financial year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Maheshwari & Co.

Chartered Accountants
Firm's Registration No.105834W

MAHESHWARI & CO. FRN 105834W MUMBAI Chartered Accountants

Vikas Asawa
Partner
Membership No. 172133
UDIN: 25172133BMHZYA2472

Place: Mumbai.
Date: May 29, 2025

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR QUARTER & YEAR ENDED MARCH 31, 2025
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Year Ended	
	Mar-25	Dec-24	Mar-24	Mar-25	Mar-24
	(Refer Note 4)	Unaudited	(Refer Note 4)	Audited	Audited
REVENUE					
Revenue from operations (net)	321.48	318.98	292.20	1,289.71	1,217.51
Other income	7.21	17.42	7.05	40.43	30.66
Total Income	**328.69**	**336.40**	**299.25**	**1,330.14**	**1,248.17**
EXPENSES					
Cost of Materials Consumed	0.09	0.05	6.00	0.23	15.78
Purchases of stock-in-trade	29.27	60.08	28.58	124.58	124.33
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	9.34	(3.20)	(9.63)	3.86	(13.33)
Employee benefits expense	39.07	44.21	35.13	152.63	136.88
Finance costs	1.00	14.27	13.85	37.62	64.44
Depreciation and amortization expense	17.45	20.12	22.57	90.99	90.59
Other expenses	172.99	104.27	141.29	601.09	591.98
Total Expenses	**269.20**	**239.81**	**237.80**	**1,011.00**	**1,010.66**
Profit/(Loss) before Exceptional Items & Tax	**59.48**	**96.60**	**61.45**	**319.14**	**237.50**
Exceptional Items	-	-	-	-	-
Profit/(Loss) Before Tax	**59.48**	**96.60**	**61.45**	**319.14**	**237.50**
Tax expense:					
Current tax	21.10	30.03	12.72	85.10	41.93
Deferred tax	(3.95)	11.03	3.06	10.99	19.18
Profit/(Loss) for the period/year	**42.33**	**55.54**	**45.67**	**223.05**	**176.39**
Items not be reclassified to profit or loss :					
Remeasurement of defined employee benefit plans	2.53	(1.56)	0.68	2.53	3.12
Income tax credit(expense) relating to above items	(2.98)	2.75	(0.17)	(0.64)	(0.78)
Other Comprehensive Income/(Loss) for the year, net of tax	**(0.45)**	**1.19**	**0.51**	**1.89**	**2.33**
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF	**41.88**	**56.73**	**46.18**	**224.94**	**178.72**
Profit/(Loss) for the year attributable to:					
Equity holders of the parent	50.83	60.90	49.83	232.78	177.61
Non-controlling Interests	(8.50)	(5.36)	(4.16)	(9.73)	(1.21)
Other Comprehensive Income/(Loss) for the year attributable to:					
Equity holders of the parent	0.06	0.52	0.17	1.67	2.21
Non-controlling Interests	(0.51)	0.67	0.34	0.22	0.12
Total Comprehensive Income/(Loss) for the year attributable to:					
Equity holders of the parent	50.89	61.42	50.00	234.45	179.82
Non-controlling Interests	(9.01)	(4.69)	(3.82)	(9.51)	(1.09)
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year				1,575.40	1,340.95
Earnings per share (EPS)					
Basic and Diluted Earing Per Share	0.21	0.38	0.25	1.15	0.87
	Not Annualized				

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2025
CIN:L85100MH2008PLC179034

(₹ in lakhs)

Particulars	As on March 31, 2025	As on March 31, 2024
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	1,904.53	1,969.24
Goodwill	210.88	350.00
Other Intangible Assets	0.99	1.03
Intangible Assets Under Development	133.25	107.25
Right-of-use assets	-	1.45
Financial Assets		
Investments	0.01	0.01
Other Financial Assets	184.95	53.27
Other Non-Current Assets	4.00	9.92
Income Tax Assets (Net)	17.62	55.71
Total Non-Current Assets	**2,456.23**	**2,547.88**
Current assets		
Inventories	79.00	80.90
Financial Assets		
Trade Receivables	184.90	52.34
Cash and Cash Equivalents	175.56	172.07
Bank Balances Other than above	3.58	252.94
Other Financial Assets	7.10	10.92
Other Current Assets	124.54	18.35
Total Current Assets	**574.68**	**587.52**
TOTAL ASSETS	**3,030.91**	**3,135.40**
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,015.68	1,015.68
Other Equity	1,575.40	1,340.95
Equity attributable to Owners of the Company	**2,591.08**	**2,356.63**
Non Controlling Interest	54.08	63.59
Total Equity	**2,645.16**	**2,420.22**
Liabilities		
Non Current Liabilities		
Financial Liabilities		
Borrowings	63.20	410.94
Other financial liabilities	44.75	5.81
Non Current Provision	17.69	15.52
Deferred Tax liabilities (Net)	142.83	130.60
Other Non Current Liabilities	8.64	-
Total Non Current Liabilities	**277.11**	**562.87**
Current Liabilities		
Financial Liabilities		
Borrowings	-	-
Lease Liabilities	-	1.56
Trade Payables		
Total Outstanding dues of Micro and Small Enterprises	0.32	0.17
Total Outstanding dues of Creditors other than Micro and Small Enterprises	29.53	21.94
Other financial liabilities	61.08	95.71
Other Current Liabilities	10.28	26.03
Current Provision	7.43	6.90
Total Current Liabilities	**108.64**	**152.31**
TOTAL LIABILITIES	**3,030.91**	**3,135.40**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025
CIN:L85100MH2008PLC179034

(₹ in lakhs)

Particulars	For Year Ended March 31, 2025	For Year Ended March 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before tax	**319.14**	**237.50**
Adjustments for:		
Depreciation and amortisation expense	90.99	90.59
Interest income	(14.39)	(20.53)
Finance costs	37.62	64.06
Bad debts	1.78	54.78
Net (gain)/loss on financial instruments	-	0.01
Provision for Gratuity	5.24	1.26
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(134.34)	50.55
(Increase)/Decrease in inventories	1.90	(14.32)
Increase/(Decrease) in trade payables	7.74	(32.20)
(Increase) /Decrease in other financial assets	(127.86)	(2.04)
(Increase)/Decrease in other assets	(100.27)	35.53
Increase/(Decrease) in other financial liabilities	4.90	1.55
Increase/(Decrease) in other liabilities	-7.11	(32.38)
Cash generated from operations	**85.34**	**434.35**
Less: Income taxes (paid)/refund	(47.01)	(33.49)
Net cash flows generated/(used) from operating activities (A)	**38.33**	**400.86**
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment and intangibles	(24.79)	(70.59)
Proceeds from disposal of property, plant and equipment and Intangibles	-	-
Intangible asset under development	(26.00)	(12.00)
Deletion of Intangible assets	139.12	
Movement in other bank balance	249.36	(39.21)
Interest received	14.39	20.53
Net cash flows generated/(used) in investing activities (B)	**352.08**	**(101.27)**
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of non current borrowings	(347.74)	(162.04)
Principal element of lease payment	(1.56)	(1.96)
Interest paid	(37.62)	(62.96)
Net cash flows generated/(used) in financing activities (C)	**(386.92)**	**(226.96)**
Net increase (decrease) in cash and cash equivalents (A+B+C)	3.49	72.65
Cash and Cash Equivalents at the beginning of the financial year	172.07	99.42
Cash and Cash Equivalents at end of the year	**175.56**	**172.07**
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with banks in current accounts	61.63	53.19
Cash on hand	113.93	118.88
Balances per statement of cash flows	**175.56**	**172.07**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Notes to the Audited Consolidated Financial Results for the yearended March 31, 2025

1. The above audited Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May29, 2025. The Statutory Auditors of the Group have carried out audit of the Consolidated financial results for the yearended March 31, 2025, and have issued an unmodified opinion on the same.

2. The above audited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. As the Group operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

4. The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the figures for the audited financial year and year to date unaudited figures up to the third quarter of the respective financial year. The figures up to the third quarter of the current financial year has been reviewed by auditors.

5. During the Quarter, following an arbitration award of ₹170 lakhs related to a non-compete dispute from a 2016 - 17 business acquisition, the Group adjusted the net proceeds of ₹139.12 lakhs (after deducting ₹30.88 lakhs in legal costs) against the original goodwill of ₹350 lakhs. The revised goodwill of ₹210.88 lakhs will be amortized over five years from FY 2025–26 in line with Ind AS 8, reflecting a change in the estimated pattern of economic benefits. An impairment review under Ind AS 36 confirmed no impairment was necessary as of the reporting date.

6. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: May 29, 2025
Place: Mumbai

Independent Auditor's Report on the Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Tejnaksh Healthcare Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying statement of consolidated annual financial results of Tejnaksh Healthcare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and financial year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us,

i. the Statement includes the results of the following Entities:

   a. Holding Company: Tejnaksh Healthcare Limited.
   b. Subsidiary: Tejvedaant Healthcare Limited.

ii. is presented in accordance with the requirements of the Listing Regulations in this regard; and

iii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group for the quarter and financial year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "*Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results*" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the

recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies/entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company/entity and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies of the entities included in the Group are responsible for assessing the ability of each company/entity to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company/entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies of the entities included in the Group is responsible for overseeing the financial reporting process of each company/entity

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieve fair presentation.

Materiality is the magnitude of misstatements in the consolidated annual financial results that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledge user of consolidated annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated annual financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The consolidated annual financial results include the results for the quarter and financial year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.105834W



Vikas Asawa
Partner
Membership No. 172133
UDIN: 25172133BMHZYB9167

Place: Mumbai
Date: May 29, 2025